ArticleMolecular endocrinology (Baltimore, Md.)2010
Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis.
Article in Molecular endocrinology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02160730 (Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine
Who cites it
36 citing papers in PubMed, 81 citations in OpenAlex.
- Management of Cushing's disease in the initial phase~From detection to surgery~.Endocrine journal · 2025Review
- Cushing syndrome.Nature reviews. Disease primers · 2025Review
- Current and Emerging Pharmacological Therapies for Cushing's Disease.Current pharmaceutical design · 2024Review
- Article
- Article
- The hallmarks of cancer… in pituitary tumors?Reviews in endocrine & metabolic disorders · 2023Review
- Review
- Preclinical Models of Neuroendocrine Neoplasia.Cancers · 2022Review
- Improving the differentiation potential of pluripotent stem cells by optimizing culture conditions.Scientific reports · 2022Article
- The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages.BMC medical genomics · 2022Article
- [Update on mechanisms of pituitary tumorigenesis.]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2021Review
- Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome.Reviews in endocrine & metabolic disorders · 2021Review
- SOX2 is required independently in both stem and differentiated cells for pituitary tumorigenesis inProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?"Cancers · 2020Review
- Molecular Mechanisms of Glucocorticoid Resistance in Corticotropinomas: New Developments and Drug Targets.Frontiers in endocrinology · 2020Review
- Effects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line.Endocrinology and metabolism (Seoul, Korea) · 2019Article
- Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.Endocrine · 2019Article
- Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease.Frontiers in endocrinology · 2018Review
- Loss-of-function mutations in theEndocrine-related cancer · 2017Article
- EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.Journal of the Endocrine Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Cushing's disease is caused by glucocorticoid-resistant pituitary corticotroph adenomas. We have previously identified the loss of nuclear Brg1 as one mechanism that may lead to partial glucocorticoid resistance: this loss is observed in about 33% of human corticotroph adenomas. We now show that Brg1 loss of function correlates with cyclin E expression in corticotroph adenomas and with loss of the cell cycle inhibitor p27(Kip1) expression. Because Brg1 is thought to have tumor suppressor activity, the present study was undertaken to understand the putative contribution of cyclin E derepression produced by loss of Brg1 expression on adenoma development. Overexpression of cyclin E in pituitary proopiomelanocortin cells leads to abnormal reentry into cell cycle of differentiated proopiomelanocortin cells and to centrosome instability. These alterations are consistent with the intermediate lobe hyperplasia and anterior lobe adenomas that were observed in these pituitaries. When combined with the p27(Kip1) knockout, overexpression of cyclin E increased the incidence of pituitary tumors, their size, and their proliferation index. These results suggest that cyclin E up-regulation and p27(Kip1) loss-of-function act cooperatively on pituitary adenoma development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.